COMMUNIQUÉS West-GlobeNewswire

MAPS Supports Therapy Education for First-Ever Department of Defense-Affiliated MDMA-Assisted Therapy Pilot
23/12/2025
Training supports multi-site clinical trial of MDMA-assisted Massed Prolonged Exposure Therapy for PTSD in active-duty service members. First-of-its-kind therapist preparation supports the Department of Defense-funded [...]
HealthLynked Announces Strategic Consulting Partnership With PBACO to Accelerate Payer Integration and Value-Based Care
23/12/2025
NAPLES, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ), a leading provider of AI-enabled patient-care coordination and healthcare interoperability solutions, today announced a [...]
Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates
23/12/2025
Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) [...]
Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
23/12/2025
- Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition consideration DUBLIN [...]
Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
23/12/2025
Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company’s CMO Dr Jason Lickliter will present a [...]
Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment
23/12/2025
Access the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve- [...]
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
23/12/2025
Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology [...]
EMJX Expands Risk-Intelligence Framework with Prediction-Market Probability Data to Enhance Treasury Stress Detection
23/12/2025
NORTH PALM BEACH, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies (“EMJX”), its digital-asset treasury operating platform, today [...]
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
23/12/2025
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores Entera's [...]
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
23/12/2025
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure. The $300 rate will apply to claims approved and paid by Medicare with [...]
MannKind Shares FUROSCIX® Business Updates
23/12/2025
FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE [...]
BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference
23/12/2025
MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
23/12/2025
ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D ( [...]
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
23/12/2025
Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based [...]
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
23/12/2025
Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of [...]
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
23/12/2025
Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) [...]
Cassava Announces Agreement to Settle Securities Class Action Litigation
23/12/2025
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous [...]
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
23/12/2025
Milestone advances manufacturing readiness and supports long-term commercialization strategy BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: [...]
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
23/12/2025
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of [...]

Pages